Cannabinoids

Cannabinoids have already started playing an important role in human health and wellbeing. The global medical cannabinoid market is expected to raise to $42.7 billion in sales by 2024.*
Since 2016 Enantia has been developing proprietary technologies to produce high quality cannabinoids. Currently we offer highly pure naturally occurring synthetic cannabinoids as well as the licensing of our cocrystallization technology platform to purify CBD, THC and other minor cannabinoids from cannabis crude extracts.

the basics

Cannabinoids are naturally occurring compounds found in the Cannabis plant.
Nowadays, cannabinoids are being studied in the treatment of a wide range of diseases, including cancer, chronic pain, depression, arthritis, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s, post-traumatic stress disorder (PTSD), Parkinson’s, Tourette’s and others. Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restrictions. Likewise, cannabinoids are also being used in cosmetics and as food additives. Different regulations for these uses apply in different countries.
travel-binoculars

our offer

Derived from our own research and development activity, Enantia offers highly pure naturally occurring cannabinoids produced synthetically, as well as the licencing of our cannabinoids purification technology.

ProDucts

All of the following highly pure cannabinoids are available to buy from a multi gram to kilogram scale.

CBD

Cannabidiol

CBD2_res

Available at kilogram scale, produced in GMP conditions

Cannabidiol is the most abundant cannabinoid found in nature and, unlike THC, it does not have any psychoactive effect. Its relaxing, anti-inflammatory and analgesic properties grabbed the attention of the scientific community since its first isolation in 1940.

CBDV

Cannabidivarin

CBDV-Cannabidivarin_res

Available in multi-gram

Cannabidivarin is a non-psychoactive cannabinoid and a structural analogue of CBD shortened by two methylene units. It is being studied mostly to evaluate its anti-epileptic properties. Current studies are focusing as well on Alzheimer’s disease and basic research is carried out to identify its mechanism of action.

CBG

cannabigerol

CBG_res

Available in multi-gram

Cannabigerol is the precursor for the biosynthesis of both CBD and THC. As a consequence, in the grown plant, the concentration of CBG is very low. It is  being studied to treat neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease and Parkinson’s disease, MS and ALS.

CBC

Cannabichromene

cbc_res

Available in multi-gram

Cannabichromene is being studied as a neuroprotector and for its anti-inflammatory properties in in vitro studies. Researchers suggest that CBC can stimulate the proliferation in neuronal stem cells. It might also be involved in modulation of other properties of cannabis extracts.

CBN

Cannabinol

CBN Cannabinol

Available in multi-gram

Cannabinol, an oxidized derivative of THC, was the first cannabinoid to be discovered and isolated. CBN is found only in trace amounts in Cannabis, and is mostly found in aged Cannabis plants. Studies report it might have a neuroprotective role in Huntington’s disease, Alzheimer’s disease, Parkinson’s disease and ALS.

purification

 

The challenge made simple

We offer you a license of our patent protected purification technology to purify CBD, THC and other minor cannabinoids from crude cannabis extracts. As a result, highly pure cannabinoids can be produced at commercial scale with a very cost effective manufacturing process.

Contact us

Enantia – Barcelona (Headquarters & Laboratories)

Baldiri Reixac, 10 (Barcelona Science Park)

08028 Barcelona

Phone +34 93 403 48 37

 

Commercial Office
Dr. Laura Grau
Phone +34 683 492 981

Enantia – Esplugues (Laboratories)

Av. Cornellà, 144

08950 Esplugues de Llobregat (Barcelona)

Phone +34 93 403 48 37

 

Commercial Office (Italy & Ticino)

Mr. Enrico Grassi

egrassi@enantia.com

Phone +39 334 796 74 34

* “2020 Update to The State of Legal Cannabis Markets” report from Arcview Group and BDS Analytics